The Mitochondrial Biogenesis and Dynamics in Health and Disease Conference

19-24 May, 2019

PalmSpring, California, USA

ENYO Pharma will be present at The Mitochondrial Biogenesis and Dynamics in Health and Disease Conference meeting from the 19th to the 24th of May at Palm Spring and presented a poster on the topic: “Chemical targeting of NEET/CISDs proteins reveals the central role of mitochondrial morphodynamics regulation in viral infection”.

Read more »

8th Congress of the International Boiron Society

8th of may, 2019
Heidelberg, Germany

Professor Rachel Nechuchstai of the Hebrew University in Jerusalem presented at the 8th Congress of the International Boiron Society in May a lecture entitled “The liability of the NEET proteins’ iron sulphur cluster: biomedical implications”. Professor Nechuchstai presented data generated in part through the close collaboration with ENYO Pharma on this topic.

Read more »

EASL (European Association for the Study of the Liver)

10-14 April, 2019
Vienna, Austria

ENYO Pharma team was present in Vienna from the 10th to the 14th of April at the EASL congress on liver diseases. On this occasion, several and fruitful discussions with various players took place. It was also the opportunity to present, in collaboration with the French research institut Inserm, a poster on the role of FXR and FXR agonists in the recruitment of HBx protein on HBV DNA.

Read more »

China Healthcare Investment Conference

26-28 March, 2019

ENYO Pharma has attended the China Healthcare Investment Conference from the 26th to the 28th of March, 2019. It was a great opportunity to initiate several financing and partneurship discussions.

Read more »

J.P. Morgan 37th Annual Healthcare Conference

7 – 10 January, 2019

San Francisco, USA

“ENYO Pharma team will be at San Francisco during the J.P. Morgan conference, which is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.” (

Read more »